Abstract
The average Adjusted Symptom Score, a new primary efficacy end‐point for specific allergen immunotherapy trials
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Paper Title
Journal
Date
